{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:09:12Z","timestamp":1789834152822,"version":"4.0.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaccao.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:20:11Z","timestamp":1776799211000},"page":"185-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy"],"prefix":"10.1016","volume":"8","author":[{"given":"Eli","family":"Grunblatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan A.","family":"Alkhalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail S.","family":"Baldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Dinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3110-8431","authenticated-orcid":false,"given":"Anjali","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jaccao.2026.02.001_bib1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.jaccao.2026.02.001_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hfc.2022.02.008","article-title":"T-cell immunotherapy and cardiovascular disease: chimeric antigen receptor T-cell and bispecific T-cell engager therapies","volume":"18","author":"Stein-Merlob","year":"2022","journal-title":"Heart Fail Clin"},{"issue":"41","key":"10.1016\/j.jaccao.2026.02.001_bib3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jaccao.2026.02.001_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.jaccao.2026.02.001_bib5","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","article-title":"Cardiovascular toxicities associated with novel cellular immune therapies","volume":"8","author":"Munir","year":"2024","journal-title":"Blood Adv"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:31:24Z","timestamp":1786404684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666087326000499"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.02.001","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}